FGF21 and Hepatic steatosis: The long-acting Fc-FGF21 fusion protein efruxifermin [144,145], along with the recombinant FGF21 analogs pegozafermin [134,135] and pegbelfermin (BMS-986036) [136], have demonstrated efficacy in improving metabolic parameters and reducing hepatic steatosis and inflammation levels in clinical trials.